A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for
…
Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.
According to Bausch’s announcement, effective Aug.
…
UPDATE, June 15, 2022, 12:45 p.m. EDT—The U.S. Centers for Medicare & Medicaid Services said, “We are aware and reviewing the decision.”
The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part
…
The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each instance of
…
Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.
In a letter this morning to its staff, the U.S. Health
…
A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities use contract pharmacies violates the 340B statute.
U.S. District Judge Leonard Stark of
…
For the first time since the 340B contract pharmacy impasse started over a year and a half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal
…
Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
According to late-day email messages from BMS to 340B
…
Biopharmaceutical company AbbVie—maker of the expensive and widely prescribed immunosuppressive medication Humira—today became the 11th drug manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.
Starting Feb. 1, AbbVie will require hospitals to submit claims
…
The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers
…*Sign up for news summaries and alerts from 340B Report